The Future of Pharma and CRO Operations: A Practical Guide to Automation
Dr. Darko Matovski, Co-founder and CEO, CausaLens
Pharmaceutical productivity is shifting from copilots to Digital Workers - AI systems that execute and oversee end-to-end operations. Unlike task assistants, they manage compliant and cross-functional workflows across R&D, clinical, and commercial functions. Early adopters like Johnson & Johnson show how automation delivers new efficiencies across the pharma and CRO value chain.
Introduction
Many pharmaceutical leaders assume productivity gains will come from copilots - conversational tools that help staff draft text or find information faster. Yet copilots remain confined to the surface of work. They assist with isolated tasks but cannot follow a process through to completion. They do not manage clinical operations budgets or respond to RFPs, for instance.
Progress will come from something broader: Digital Workers - end-to-end AI systems built to run the operational flows that hold these organisations together. These are effectively 24/7 colleagues who continually run and monitor different operational processes. They connect actions and decisions across teams, execute within defined governance, and make their reasoning transparent enough to trust.
Johnson & Johnson and Syneos Health are already showing how AI can reshape core operations in regulated industries. Their adoption marks a shift from isolated automation to integrated systems capable of managing complex, cross-functional workflows with high reliability. This is not about chatbots or simple RPA; it is about applying intelligent systems to the operational backbone of pharmaceuticals and clinical research. As traditional tools reach their limits, Digital Workers are emerging as the next step in achieving precision and scalability across the value chain.
Analysts forecast that the AI in pharma and biotech markets will surge to $13.1 billion by 2034 - underscoring that this is not a passing experiment but a structural shift (Transparency Market Shift).
Translating AI Capability into Practical Operational Functions
Turning AI capability into operational value requires more than enterprise access to an LLM; it demands integration with the day-to-day realities of pharmaceutical work. Any kind of GxP industry needs to first ensure that its Digital Workers are compliant. This means audit trails, causal reasoning integrations, and region-specific rules for the US (FDA/SOX) or EU/UK (EMA/GDPR).
Once this has been validated, the next step is to identify a use case that can deliver measurable results. Many AI initiatives struggle to move beyond the pilot stage - studies suggest that up to 95% fail to generate a return on investment (Fortune). This is often because they are tested in isolation rather than implemented within real, dynamic operational environments. For pharmaceutical and life sciences organisations, success begins with automating the most repetitive and manual processes - often referred to as “Level 1” tasks.
Real-World Pharma Use Cases
RFP Responder
- Challenge: Responding to RFPs is often an unstructured, labour-intensive process. Teams spend hours searching through old proposals, copying sections by hand, and coordinating last-minute edits under deadline pressure. The result is inconsistent quality and rising costs per submission.
- Digital Worker Impact: The Digital Worker reviews new RFPs, locates relevant material from previous documents, and assembles an initial draft automatically. It keeps structure, tone, and references consistent, giving teams a reliable starting point instead of a blank page.
- Business Result: Proposals are completed more quickly and with fewer errors. The process becomes more predictable, freeing up time for reviewers to focus on content accuracy and strategy rather than administration.
Marketing Operations Worker for MLR Review
- The Challenge: The MLR review process is notorious for slowing everything down. Campaigns stall for weeks as materials bounce between reviewers, delaying launches and revenue.
- How the Digital Worker Helps: It screens every piece of content before review, checking it against approved product data, brand policies, and previous approvals. Potential red flags are highlighted automatically, so reviewers only deal with what truly needs attention.
- The Result: Reviews that used to take weeks can now be done in days. Marketing teams can launch campaigns faster, reviewers focus on higher-value work, and compliance risk drops. The process becomes faster, cleaner, and far less painful.
Medical Info & Safety Intake Worker
- The Challenge: Call centers are critical for collecting safety data, but manual handling of adverse events and product complaints is slow and prone to mistakes, which creates compliance and patient safety risks.
- Digital Worker Impact: It integrates directly with contact center tools and digital channels. Using natural language processing, it detects safety events as they come in, walks agents through a compliant data-capture process, and automatically sends clean, coded cases into systems like Oracle Argus or Veeva.
- The Result: Processing speeds up dramatically while accuracy and compliance improve. Teams get inspection-ready data and stronger safety oversight — all without adding staff.
Sales Territory Alignment Worker
- The Challenge: Pharma sales teams often rely on outdated or inconsistent territory maps, leading to poor coverage, inefficiency, and friction with reps. Fixing it manually requires reconciling large amounts of messy customer, product, and performance data.
- Digital Worker Impact: It ingests CRM and market data, applies causal reasoning to design optimal rep-to-territory assignments, and produces transparent alignment scenarios that factor in compliance rules, workload fairness, and key account continuity.
- The Result: Territory plans that once took weeks can now be built in hours. Coverage improves, reps are more productive, and leadership gets clear, data-driven justification for every assignment — unlocking growth while reducing operational drag.
Grant Variance Intelligence & Reforecasting Worker
- Challenge: Clinical trial grants are set once, but visit mixes, pass-throughs, and FX drift daily. By the time finance notices, margins are already bleeding and site payments lag.
- Digital Worker Impact: The worker continuously reconciles plan vs[Ma1] . Actuals, explains what changed, and updates the forecast on the fly. It prompts the right adjustment before problems pile up.
- Business Result: Sponsors protect margin and keep sites motivated with timely payments. Trials stay financially on track and hit milestones without last-minute firefighting.
Scope of Work (SOW) Digital Worker
- Challenge: In clinical programs, financial losses often stem not from the contract itself but from how work is executed and tracked. Ambiguities in scope definitions and informal approvals make it difficult to maintain alignment between contracted work and actual delivery. That uncertainty causes margin slippage and delayed billing.
- Digital Worker Impact: The Scope of Work Digital Worker turns static agreements into active oversight. It reads SOWs and MSAs from CLM systems, understands the contracted scope, and monitors live activity in CTMS, collaboration, and ERP platforms. When work drifts, it flags the issue and prepares a clear change order for review. Once milestones meet acceptance criteria, it assembles the invoice packet automatically and sends it for approval.
- Business Result: Projects maintain financial accuracy and stability. Better visibility into scope and delivery supports timely billing and stronger audit readiness.
These are not unlocking 5% efficiency gains, but delivering order-of-magnitude improvements - reducing cycle times and costs in a way that AI copilots simply cannot achieve.
The Evidence for Automation
The shift to automation is already creating a measurable impact across the industry. Pharma companies, like Syneos Health and Johnson & Johnson, are seeing dramatic improvements in efficiency and quality with Digital Workers.
Agentic AI, the technology powering Digital Workers, is recognized by firms like Gartner and McKinsey as a key business trend. The numbers speak for themselves. In biopharma operations, McKinsey reports that AI-assisted deviation and CAPA management can lead to fewer deviations and 30-40% faster closure times (McKinsey). In manufacturing, one midsize European player used AI analytics to achieve a 29% increase in throughput in upstream bioprocessing (McKinsey).
The impact is equally transformative in pharmacovigilance (PV). Traditional case processing is notoriously slow and manual. However, analyses from IQVIA project that AI-powered Digital Workers can compress case processing timelines from a week to approximately 24 hours (IQVIA). This acceleration enables safety teams to detect signals faster and ensure more robust compliance.
The Emergence of Hybrid Teams
Recent research from MIT shows that when human workers collaborate with AI agents, individual productivity increases by roughly 60% compared to human-only teams (MIT). These hybrid teams also communicate more efficiently, sending fewer coordination messages and focusing more time on substantive tasks such as decision-making.
The benefit comes from a clear division of labor. Digital Workers handle consistency and
data-heavy pattern recognition, while humans focus on oversight. In pharmaceutical R&D, this “Human-in-the-Loop” model is already emerging: AI generates hypotheses and performs computational analysis, while scientists review results and guide experimental strategy. Roche’s “lab-in-the-loop” approach exemplifies this, using feedback cycles where experimental outcomes refine AI models, which in turn improve the next iteration of research (Roche).
Conclusion:
Making Automation a Core Capability
Digital Workers are moving from pilot projects to core infrastructure in pharmaceutical and CRO operations. Their adoption signals a shift from small-scale automation to a new operational model built on precision, auditability, and real-time adaptability. The most effective organisations are integrating these systems into existing workflows, using them to manage complexity and ensure consistent performance across global programs.
What’s emerging is a more connected and resilient way of running critical processes. Workflows that once depended on manual coordination are now continuously monitored and adjusted in real time. Compliance checks happen automatically, and deviations are surfaced before they become costly errors. Decision-makers gain clearer visibility into how projects progress and where interventions are needed. This operational transparency creates a foundation for faster, more confident execution.
References:
- Fortune. (2025, August 18). MIT report: 95 percent of generative AI pilots at companies failing, CFO says. Retrieved from https://fortune.com/2025/08/18/mit-report-95-percent-generative-ai-pilots-at-companies-failing-cfo/
- HCAMag. (2025). MIT study reveals huge impact of AI agents on productivity. Retrieved from https://www.hcamag.com/ca/news/general/mit-study-reveals-huge-impact-of-ai-agents-on-productivity/540531
- IQVIA. (2025). Generative AI: The future of pharmacovigilance (White Paper). Retrieved from https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/generative-ai-the-future-of-pharmacovigilance-white-paper.pdf
- McKinsey & Company. (2025). Gen AI: A game changer for biopharma operations. Retrieved from https://www.mckinsey.com/industries/life-sciences/our-insights/gen-ai-a-game-changer-for-biopharma-operations
- McKinsey & Company. (2025). Human–machine harmonization to upgrade biopharma production. Retrieved from https://www.mckinsey.com/capabilities/operations/our-insights/human-machine-harmonization-to-upgrade-biopharma-production
- Roche. (2025). AI revolutionising drug discovery and transforming patient care. Retrieved from https://www.roche.com/stories/ai-revolutionising-drug-discovery-and-transforming-patient-care
- Transparency Market Research. (2025). AI in pharma and biotech market. Retrieved from https://www.transparencymarketresearch.com/ai-in-pharma-and-biotech-market.html
Dr. Darko Matovski is the co-founder and CEO of causaLens, a London-based company pioneering multi-agentic systems that automate enterprise workflows. He holds a PhD in Computer Science and an MBA from the University of Southampton, and has a background in quantitative research and Computer Engineering.
